Biogen Idec is pleased to announce that Plegridy (peginterferon beta-1a) has been approved by the Therapeutic Goods Administration (TGA) for treatment of adults with relapsing forms of multiple sclerosis (RMS). Plegridy is the first pegylated beta interferon to be approved for RMS, and is only required to be injected once every two weeks. It is anticipated that Plegridy will be available on the Pharmaceutical Benefits Scheme in the first half of 2015. 

"We are delighted that patients with MS are now one step closer to having access to Plegridy in Australia," said Joerg Hermans, Managing Director, Biogen Idec Australia and New Zealand. 

"As a company with a strong heritage of innovation in MS, we know the disease affects individuals differently, and we are committed to providing a range of treatment options which meet their needs. We look forward to providing Plegridy as an option for patients in Australia, particularly as it provides dosing once every two weeks."

For more details, go to: http://www.firstwordpharma.com/node/1245390#axzz3IjlwLAka